Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab

Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab

BackgroundMerkel cell carcinoma (MCC) is a rare and aggressive skin cancer, associated with a worse prognosis. The Immune Checkpoint Inhibitors (ICIs) avelumab and pembrolizumab have been recently approved as first-line treatment in metastatic MCC (mMCC). The clinical observation of improved outcome...

Full description

Bibliographic Details
Main Authors: Lorena Incorvaia, Alessandra Dimino, Laura Algeri, Chiara Brando, Luigi Magrin, Ida De Luca, Erika Pedone, Alessandro Perez, Roberta Sciacchitano, Annalisa Bonasera, Tancredi Didier Bazan Russo, Federica Li Pomi, Marta Peri, Valerio Gristina, Antonio Galvano, Dario Giuffrida, Ivan Fazio, Francesca Toia, Adriana Cordova, Ada Maria Florena, Antonio Giordano, Viviana Bazan, Antonio Russo, Giuseppe Badalamenti
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-04-01
Series:Frontiers in Oncology
Subjects:
Merkel cell carcinoma (MCC)
avelumab
body mass index - BMI
predictive factors
immunotherapy
skin cancer non melanoma
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1141500/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1141500/full

Similar Items